Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
305
resultados
Última actualización
14/07/2026 [08:22:00]
Resultados 50 a 75 de 305
Resumen de: US20260177560A1
A process for determining an extent of a central nervous system (CNS) specific neurological condition in a subject including collecting a biological sample of biofluid from the subject and measuring a quantity of a first biomarker, or metabolite of or mRNA corresponding to, the first biomarker from the sample from a dried spot or through a microfluidic device. The biofluid is capillary blood or saliva, which affords ease of collection advantages that are attractive for field-, hospital-, and home-based environments. The process being useful in the diagnosis, care, and management of brain specific abnormal neurological conditions in general, and in particular, to traumatic brain injury (TBI) and (TBI-induced) Alzheimer's disease (AD) and Alexander disease, in which a GFAP mutation is implicated in white matter deterioration.
Resumen de: US20260176364A1
0000 The invention relates to compositions and methods for producing and using antibodies against the alpha7 nicotinic acetylcholine receptor.
Resumen de: US20260177546A1
The invention provides a method for predicting the susceptibility of a patient suffering from a cancer or a myeloid-mediated disease to immunotherapy. Furthermore, the invention provides a method for treating a patient suffering from a cancer or a myeloid-mediated disease with immunotherapy. In accordance with these embodiments, the inventive method includes assaying myeloid cells obtained from the patient prior to treatment for the expression of CXCR3. The invention also provides a genetically engineered myeloid cell (GEMy) in which the expression of CXCR3 is modulated (up- or down-regulated). The invention further provides a composition comprising the inventive GEMy and a pharmaceutically acceptable carrier. The invention also provides a method for treating a patient in need of immunotherapy comprising administering the inventive composition to a patient.
Resumen de: US20260177544A1
An object of the present invention is to provide a highly sensitive method for detecting a biomarker. The object can be achieved by a method for detecting a test substance in a specimen of the present invention, the method being (A) a sandwich method including: (1) bringing a specimen into contact with a magnetic particle on which a primary substance is immobilized and which has a particle diameter that does not cause interference with a wavelength for measurement with a laser, to form a primary substance-test substance complex of the primary substance and a test substance in the specimen; (2) bringing the primary substance-test substance complex into contact with a secondary substance, to form a primary substance-test substance-secondary substance complex of the primary substance-test substance complex and the secondary substance; and (3) detecting the primary substance-test substance-secondary substance complex on the magnetic particle with a laser; or (B) a competitive method including: (1) bringing a specimen and a secondary substance into contact with a magnetic particle on which a primary substance is immobilized and which has a particle diameter that does not cause interference with a wavelength for measurement with a laser, to form a primary substance-secondary substance complex of the primary substance and the secondary substance; and (2) detecting the primary substance-secondary substance complex on the magnetic particle with a laser.
Resumen de: US20260176315A1
Use of an interleukin 27 (IL-27) protein in preparation of a product for treating and/or delaying Alzheimer's disease (AD) is provided, belonging to the technical field of biomedicine. The IL-27 protein refers to a recombinant IL-27 protein targeting a therapeutic target IL-27, and is selected from the group consisting of a mouse-derived IL-27 protein and a human-derived IL-27 protein, as well as a mammalian IL-27 protein other than the mouse-derived IL-27 protein and the human-derived IL-27 protein. The recombinant IL-27 protein can effectively alleviate the AD caused by Aβ deposition, and can selectively bind to a target receptor, thereby ensuring an accuracy of test results. The protein receptor is highly expressed in the dentate gyrus region of hippocampus, and guarantees drug targeting to the greatest extent.
Resumen de: US20260176332A1
0000 The present application relates to a marker and a method for detecting inflammation-related diseases. The marker of the present application can stably exist in an ex vivo body fluid sample and does not gather on a cell membrane, so the detection result is very accurate. The marker can be widely applied to the medical detection of inflammation-related diseases, having good clinical application prospects.
Resumen de: WO2022118944A1
The present invention addresses the problem of providing: a method for evaluating dementia; and a composition for preventing or treating deterioration in brain function, or maintaining or improving brain function. The intestinal microflora of healthy people, people with mild cognitive impairment, or patients suffering from Alzheimer's disease were compared. As a result, a microorganism belonging to the genus Faecalibacterium was selected as an intestinal microorganism associated with cognitive function. Furthermore, it has been found that Faecalibacterium prausnitzii having a specific DNA exhibits an effect of ameliorating brain function deterioration such as learning and memory impairment.
Resumen de: US20260177562A1
Methods of measuring the amount of singly- or multiply-phosphorylated p217+ tau protein in a sample are provided. Methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of a treatment of a tauopathy, and methods of determining whether a subject is suitable for anti-p217+ tau antibody therapy are also provided. Also described are antibodies for use in the methods and kits comprising the antibodies.
Resumen de: WO2026134722A1
The present invention relates to a PTEN oxidative inactivation inducer comprising 1,1-diethoxyethane as an active ingredient and use thereof. More specifically, the present invention relates to: a PTEN oxidative inactivation inducer comprising 1,1-diethoxyethane (1,1-DEE) as an active ingredient; and use thereof, for example, a pharmaceutical composition, a cosmetic composition, a food composition, or a feed composition, as a composition for preventing, treating or ameliorating diseases requiring the oxidative inactivation of PTEN, and a method for detecting PTEN redox state.
Resumen de: AU2024406255A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the efficacy of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function and/or quality of life.
Resumen de: WO2026135697A1
Patients suffering from, or at risk of developing the symptoms of, Alzheimer's disease and related neuroinflammatory-based diseases, are treated by apheresis to selectively withdrawal Galectin-3 from the patient's body. A reduction in the circulating level of gal-3 of the patient of at least 30% of the patient's pre-treatment galectin-3 level should be sufficient to reduce AD symptoms, and/or inhibit AD progression. A greater withdrawal, up to at least 20%, has greater impact. Selective withdrawal of Galectin-3 may be coupled with the administration of MCP to further slow the progress of, and/or reverse, AD symptoms.
Resumen de: US20260177563A1
0000 Disclosed is a sample analyzer comprising: a measurement unit configured to measure an analyte related to a dementia biomarker contained in a sample collected from a subject, the measurement unit comprising: a sample dispenser configured to aspirate the sample from a sample container and discharge the aspirated sample into a cuvette, a first reagent dispenser configured to aspirate a first reagent from a first reagent container and discharge the aspirated first reagent into the cuvette, wherein the first reagent immunologically reacts with the analyte, a second reagent dispenser configured to aspirate a second reagent from a second reagent container and discharge the aspirated second reagent into the cuvette, wherein the second reagent generates light corresponding to an amount of the reacted analyte, a detector configured to detect the generated light from a mixture of the sample, the first reagent, and the second reagent in the cuvette; a controller comprising a processor and programmed to obtain a measurement value of the analyte based on the light detected by the detector; a storage configured to store a reference value that specifies an outlier that may be caused by a factor other than dementia; and an output unit, wherein the controller is programmed to execute a determination on whether the measurement value is specified as the outlier based on the measurement value and the reference value, generate an analysis result of the dementia biomarker based on the mea
Resumen de: WO2026132413A1
The present invention relates to an antibody or antigen-binding fragment thereof, which binds to TDP-43, i.e. TAR DNA-binding protein 43, and to therapeutic and diagnostic uses thereof.
Resumen de: WO2026132444A1
The present invention relates to in vitro methods for diagnosing or prognosing diseases and disorders associated with altered orexin-A levels. It further relates to in vitro methods for monitoring the effect of a treatment or the evolution of a disease or disorder associated with altered orexin-A levels. It also relates to the use of orexin-A fragment as biomarker for the in vitro diagnosis of diseases and disorders associated with altered orexin-A levels.
Resumen de: DE102024139461A1
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung eines In-vitro-Modells für eine neurologische Erkrankung des Menschen. Darüber hinaus betrifft die Erfindung das gemäß dem hierin offenbarten erfindungsgemäßen Verfahren hergestellte In-vitro-Modell. Außerdem betrifft die Erfindung die Verwendung des In-vitro-Modells der Erfindung bei Arzneimitteltests. Darüber hinaus betrifft die Erfindung Verfahren zum Testen der Wirksamkeit von Arzneimitteln bei der Vorbeugung, Verzögerung und Linderung einer neurologischen Erkrankung des Menschen.
Resumen de: WO2026134539A1
The present invention relates to a DNA aptamer specifically binding to an alpha-synuclein protein and uses thereof. Specifically, the present invention relates to a DNA aptamer selected from the group consisting of nucleotide sequences of SEQ ID NOS: 1 to 12 and binding specifically to an α-synuclein protein, and a composition for detecting an α-synuclein protein, a detection kit, a detection chip or a microarray, all comprising the aptamer as an active ingredient. In addition, the present invention relates to a method for detecting an α-synuclein protein, a method for providing information for diagnosing a degenerative brain disease, a composition for diagnosing a degenerative brain disease, and a pharmaceutical composition for preventing or treating a neurodegenerative disease, all using the DNA aptamer of the present invention.
Resumen de: WO2026134051A1
This plasmalogen detection method comprises: a sample preparation step for mixing a Schiff's reagent and a specimen containing a plasmalogen to obtain a sample; a reaction step for reacting the plasmalogen in the sample with the Schiff's reagent; and a contact step for bringing at least some of the sample reacted in the reaction step into contact with a stationary phase containing a silica gel.
Resumen de: EP4764499A1
0001 The present invention relates to a method of detection of glycated proteins, particularly gHSA, which comprises the steps of: i) providing anthracene boronic acid methacrylate (ABAM): 10-N-methyl-N-(o-boronobenzyl)aminomethyl-anthracene-9-methyl methacrylate; ii) preparing a solution of ABAM in a biocompatible buffer with pH in the range of from 6.5 to 8.5 or in in vitro blood plasma sample of a healthy subject; iii) measuring initial fluorescence intensity of ABAM solution from step ii) at the wavelength of from 410 to 520 nm; iv) in vitro mixing of a known amount of ABAM solution from step ii) with a known amount of biological sample; v) measuring fluorescence intensity of the mixture from step iv) at the wavelength of from 410 to 520 nm; vi) determining the fluorescence intensity increases between the initial control fluorescence intensity measured in step iii) and the fluorescence intensity of the mixture of ABAM and biological sample measured in step v); vii) calculating the amount of glycated proteins in the biological sample. 0002 The present invention further relates to the use of this method in determination of the total concentrations of glycated proteins, particularly gHSA, in plasma samples and diagnostics for diabetes mellitus.
Resumen de: WO2025040574A1
Alzheimer's disease is strongly linked to biological aging and bioenergetic abnormalities. Systemic dysregulation of metabolism is a hallmark of the physiological decline of tissues with age. We aimed to explore untargeted metabolomic profiling of blood samples from amyloid-positive people to distinguish individuals who progressed to cognitive decline from those who remained cognitively intact despite having amyloid deposits in the brain. A minimal signature of 9 metabolites identified decliners and non-decliners of cognitive function in participants with an amyloid load. These findings are of clinical importance as they suggest that a metabolic fingerprint may help to predict patients who will develop cognitive decline. Due to the high prevalence of brain amyloid-positivity in older adults, identifying adults who will have cognitive decline will enable the development of personalized and early interventions. The present invention relates to an in vitro method for predicting cognitive decline in a subject comprising the step of determining the level of at least one metabolite selected in the group consisting of 3-hydroxybutyrate, acetone, triglyceride 48:3, glucose, citrate, succinate, methionine, serine, sphingomyelin d18:1/C26:0 in a biological sample obtained from the subject.
Resumen de: EP4763997A1
The present invention relates to biomarkers capable of diagnosing various brain and nervous system diseases, and a method of providing information for diagnosing brain and nervous system diseases using the same. According to the present invention, it is possible to diagnose, at an early stage, the onset of a brain and nervous system disease or the likelihood of developing the disease or diagnose the progress or prognosis of the disease or the therapeutic effect against the disease, by measuring the expression level of the biomarker protein of the present invention or a gene encoding the same in the aqueous humor of the eye.
Resumen de: CN122255284A
本发明涉及生物技术领域，具体的，本发明公开了一种酪氨酸碘化修饰PP2A蛋白的单克隆抗体、制备方法及应用。本发明通过制备酪氨酸碘化修饰的PP2A蛋白抗原肽，免疫兔制备单克隆抗体，并利用噬菌体展示技术淘选、表达载体扩增和ELISA筛选，最终获得一株能有效识别靶标的单克隆抗体R004。该抗体在免疫组织化学、细胞免疫荧光和蛋白免疫印迹中均表现出良好的灵敏度和特异性。本发明筛选得到的单克隆抗体可以用于PP2A蛋白催化亚基307位酪氨酸碘化修饰的检测中，为肿瘤诊断、抗肿瘤和神经疾病药物的研发提供支持。
Resumen de: CN122256501A
0001 本发明涉及生物医药领域，具体涉及偏头痛诊断的生物标志物、试剂盒及其应用。本发明所述的偏头痛疾病相关的生物标志物包括COL4A2，同时还包括MMP‑14、LCAT、ADAMTS13和CPXM2中的任意一种或多种的组合。本发明基于临床健康对照和偏头痛患者的蛋白质组学数据，应用生信分析和机器学习等方法，深入挖掘对偏头痛疾病诊断最有预警价值的蛋白质组合，并在扩大样本的临床队列中进行验证，为新发现的生物标志物的临床转化提供良好前景，同时也为后续机制研究奠定基础。
Resumen de: CN122259816A
本发明涉及一种用于脑类器官药物测试的实时监测方法和系统，包括如下步骤：S1、进行脑类器官的制备与预培养；S2、微电极阵列芯片与反应微室的准备：将芯片安装于反应微室中，所述反应微室中央设计花瓣式流体槽结构，中心为样本腔体，外围的花瓣槽道与入口和出口流道相连；S3、脑类器官的装载与固定：在下层微电极阵列电极中心放置脑类器官后放置上层微电极阵列芯片，使脑类器官被夹持在上下电极之间，保证接触充分但不造成压伤；S4、药物灌注与电生理实时监测：将药物沿流道进入花瓣式流体槽并扩散至反应腔体，实时记录脑类器官电信号变化；S5、进行系统清洗与复用。
Resumen de: WO2024235879A1
The invention relates to a nasal fluid sample obtained from a subject comprising the marker protein(s) β amyloid (Aβ), phosphorylated Tau (pTau) and/or total Tau (tTau). The invention further relates to a nasal fluid sample comprising the marker protein(s) Aβ, pTau and/or tTau for use in a method for the aid in diagnosis of neurodegenerative diseases and the use of a nasal fluid sample comprising the marker protein(s) Aβ, pTau and/or tTau for the aid in diagnosis of a neurodegenerative disease. The invention further relates to a method for the aid in diagnosis of a neurodegenerative disease in a subject/individual.
Nº publicación: JP2026520292A 23/06/2026
Solicitante:
アボットポイントオブケアインコーポレイテッド
Resumen de: US2025003990A1
0000 Disclosed herein are improved assays, cartridges, kits, and methods of use thereof for detecting biomarkers, e.g., one or more biomarkers of brain injury, including, without limitation, biomarkers of acquired brain injury (ABI), such as, traumatic brain injury (TBI). The improved assays described herein may aid in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head (e.g., TBI) by detecting levels of a biomarker, such as UCH-L1, GFAP, or a combination thereof, in samples taken from a subject (e.g., a human subject).
BOPI
Sede Electrónica
